Vitamin K2 (MK-7): Bone, Arteries & The Case for Pairing with D3
⚡ 60-Second Summary
Vitamin K is actually two families. K1 (phylloquinone) comes from leafy greens and dominates the typical diet — it's mostly consumed by the liver for clotting. K2 (menaquinones) comes from animal foods, fermented foods, and some gut-bacterial synthesis. K2 has subtypes labeled MK-4 through MK-13.
MK-7 — produced by Bacillus subtilis fermentation (the same organism that makes natto) — has a half-life of roughly 3 days, versus MK-4's few hours. That's why MK-7 supports once-daily dosing at modest microgram amounts, while MK-4 only works as a pharmaceutical megadose.
K2 activates two Gla proteins that matter clinically: osteocalcin (deposits calcium into bone) and matrix Gla protein (keeps calcium out of arterial walls).
Adequate Intake (no formal RDA): 90 µg/day for women, 120 µg/day for men, total vitamin K. Typical MK-7 supplement dose: 90–180 µg/day with a fatty meal.
What is vitamin K?
"Vitamin K" is a family of fat-soluble compounds built around a 2-methyl-1,4-naphthoquinone backbone. They differ in the side chain hanging off that backbone:
- Vitamin K1 (phylloquinone) — single phytyl side chain. Made by plants and concentrated in green leafy vegetables (kale, spinach, collards, broccoli). This is the dominant dietary form in most Western diets.
- Vitamin K2 (menaquinones, MK-n) — an isoprenoid side chain of variable length, denoted "MK-n" where n is the number of isoprene units (4 to 13). The two clinically relevant forms are MK-4 (also called menatetrenone — used in Japan as a prescription osteoporosis treatment) and MK-7 (the natto-derived long-chain form used in most modern supplements).
- Vitamin K3 (menadione) — a synthetic, water-soluble form. Not used in human supplements due to toxicity at higher doses; mostly an animal-feed additive.
All forms ultimately function as a cofactor for the enzyme γ-glutamyl carboxylase, which adds a carboxyl group to specific glutamate residues on "Gla proteins." That extra carboxyl lets the protein bind calcium. Two Gla proteins explain almost all of the clinical interest in K2 specifically:
- Osteocalcin — secreted by osteoblasts; in its carboxylated form it binds calcium hydroxyapatite and helps deposit it into bone matrix.
- Matrix Gla protein (MGP) — expressed in vascular smooth muscle; in its carboxylated form it actively inhibits calcium phosphate crystal formation in arterial walls.
According to the NIH Office of Dietary Supplements, K1 is preferentially taken up by the liver to drive the coagulation cascade (factors II, VII, IX, X, protein C, protein S), while menaquinones — and MK-7 in particular — circulate longer and reach extrahepatic tissues like bone and vasculature more reliably.
Evidence-based benefits of vitamin K2 supplementation
1. Bone density in postmenopausal women
The strongest single trial is Knapen et al. 2013: a 3-year, double-blind RCT of 244 healthy postmenopausal women randomized to 180 µg/day MK-7 (as MenaQ7) or placebo. The MK-7 group showed significantly less age-related decline in bone mineral density at the lumbar spine and femoral neck, along with improvements in markers of osteocalcin carboxylation. The absolute effect size is smaller than what bisphosphonates produce, but MK-7 was very well tolerated and is plausible as an adjunct rather than a replacement for fracture-risk drugs.
2. Vascular calcification
The mechanistic case is strong: matrix Gla protein is the body's main local brake on arterial calcification, and it requires K2 to function. The headline observational signal is the Rotterdam Study (n=4,807 followed ~7 years), in which the highest tertile of dietary K2 (menaquinone) intake was associated with significantly lower coronary calcification and lower cardiovascular mortality, while K1 intake showed no such association. This is hypothesis-generating, not proof. Hard-outcome RCTs (e.g., the InterVitaminK trial program) are still maturing.
3. K2 + vitamin D3 — biological synergy
The pairing has a clean mechanistic story even if the combination-trial data are still thin. Vitamin D3 increases intestinal calcium absorption, raising the amount of calcium available to circulate. Vitamin K2 then governs where that calcium lands: carboxylated osteocalcin pulls it into bone matrix, carboxylated MGP keeps it out of arterial walls. The implication that "D3 without K2 risks calcifying arteries" is overstated in supplement marketing — most people on a normal diet have enough K to carboxylate MGP — but for individuals on high-dose D3, supplementing modest K2 alongside is a low-risk hedge.
4. Cardiovascular events
Observational data (Rotterdam Study, the PROSPECT-EPIC cohort) suggest higher menaquinone intake correlates with fewer hard cardiovascular events, but no RCT has yet shown that supplemental K2 reduces myocardial infarction or cardiovascular mortality. Several trials are in progress; treat any "K2 prevents heart attacks" claim as premature in 2026.
Deficiency and insufficiency
Frank vitamin K deficiency — measured as a prolonged prothrombin time / abnormal INR — is rare in adults because gut bacteria and a varied diet usually keep the coagulation machinery supplied. The more interesting clinical phenomenon is K2 insufficiency: enough K1 to keep clotting normal, but not enough activated K2 to fully carboxylate extrahepatic Gla proteins. Researchers measure this indirectly via "undercarboxylated osteocalcin" (ucOC) and "dephospho-uncarboxylated MGP" (dp-ucMGP), both of which run high in much of the general adult population.
Watch for higher risk of frank deficiency in:
- People on therapeutic warfarin/coumarin (the deficiency is the intent of the drug)
- Fat malabsorption — celiac, Crohn's, cystic fibrosis, biliary obstruction, post-bariatric surgery, chronic pancreatitis
- Long-term broad-spectrum antibiotic use (suppresses gut menaquinone synthesis)
- Newborns — physiologically low K stores; a single IM dose at birth is standard prophylaxis against vitamin K deficiency bleeding
- End-stage liver disease
For details on how K status is assessed, see how to test vitamin K status.
MK-4 vs MK-7 (and the other forms), compared
The form on the label, and the dose, determine whether a K2 product is doing anything:
| Form | Best for | Typical dose | Notes |
|---|---|---|---|
| MK-7 (natto-derived) | Long-term daily supplementation | 90–180 µg/day | Half-life ~3 days. Stable serum levels with once-daily dosing. The form used in the Knapen 2013 bone trial. |
| MK-4 (synthetic / menatetrenone) | Rx megadose for osteoporosis (Japan) | 45 mg/day (15 mg × 3) | Half-life only a few hours, so requires very high split doses. Roughly 250× the µg load of MK-7 protocols, and far more expensive. |
| K1 (phylloquinone) | Coagulation; warfarin reversal | Diet covers most needs | Excellent for clotting-factor synthesis; less effective than K2 at activating extrahepatic Gla proteins (bone, vascular). |
| MK-9, MK-13 (long-chain menaquinones) | Mostly dietary (cheese, gut bacteria) | Not standardized | Less studied in humans. Found in fermented dairy. Not commonly sold as isolated supplements. |
| D3 + K2 combo softgels | Convenience for people on high-dose D3 | ~5,000 IU D3 + 100 µg MK-7 | Reasonable pairing if you'd take both anyway. Check the K2 form is MK-7, not MK-4 at a token sub-mg dose. |
For a deeper side-by-side, see MK-4 vs MK-7 and Vitamin K1 vs K2.
How much vitamin K2 should you take?
The U.S. Institute of Medicine has not set a formal RDA for vitamin K — only an Adequate Intake (AI) for total K (K1 + K2 combined):
- Men 19+: 120 µg/day
- Women 19+: 90 µg/day
These AI values are calibrated to maintain normal blood coagulation, not to maximally carboxylate osteocalcin or MGP — which is why some researchers argue typical intakes are "enough for clotting, not optimal for bone."
Practical MK-7 dosing:
- 90–180 µg/day of MK-7, taken with the largest fatty meal of the day (it is fat-soluble). 180 µg is the dose used in the Knapen 3-year trial.
- Once-daily timing is fine because MK-7's half-life is ~3 days.
- Do not switch protocols if you are on warfarin without telling the prescriber (see interactions).
MK-4 protocol: 45 mg/day in 3 divided doses is the Japanese pharmaceutical regimen for osteoporosis. Do not attempt this without a clinician who is actually managing osteoporosis treatment.
Tolerable Upper Intake Level: No UL has been established for vitamin K. Trials have used MK-7 up to several mg/day without significant adverse effects, and MK-4 at 45 mg/day for years. The practical ceiling is set by the warfarin interaction in anticoagulated patients, not by toxicity in everyone else.
Side effects
Vitamin K2 — both MK-4 and MK-7 — is among the better-tolerated fat-soluble vitamins in supplement use. Reported side effects are uncommon and generally mild:
- Mild GI upset, loose stools (especially when taken on an empty stomach)
- Occasional flushing or skin reactions
- Headache (rare)
The clinically meaningful safety question is not toxicity. It is the warfarin interaction, covered next.
Drug interactions to know about
Warfarin and other coumarin anticoagulants
Warfarin works by blocking vitamin K recycling in the liver, depleting active clotting-factor synthesis. Vitamin K — including K2 — directly antagonizes that effect. The clinically correct rule is consistency, not abstinence: a stable daily K intake lets your prescriber titrate the warfarin dose to a stable INR. The dangerous behaviour is starting, stopping, or sharply changing a K supplement (or your green-vegetable intake) without telling the clinician. Do not begin a K2 supplement while on warfarin without a conversation with the prescriber and a follow-up INR.
Direct oral anticoagulants (DOACs)
Apixaban, rivaroxaban, dabigatran, and edoxaban do not act through the vitamin K cycle. They have no significant vitamin K interaction, and people on DOACs do not need to limit dietary or supplemental K2 for that reason.
Bile-acid sequestrants and orlistat
Cholestyramine, colestipol, colesevelam, and the weight-loss drug orlistat all reduce absorption of fat-soluble vitamins, including K. People on chronic therapy should separate doses by at least 2 hours and consider periodic monitoring of K-dependent function (PT/INR).
Long-term broad-spectrum antibiotics
Multi-week courses of broad-spectrum antibiotics suppress the gut bacteria that synthesize menaquinones. This is rarely clinically significant on its own, but it can tip a borderline-deficient or anticoagulated patient into a meaningful change in K status.
Check our free interaction checker for a complete list.
Frequently asked questions
What's the difference between vitamin K1 and K2?
K1 (phylloquinone) is the form abundant in leafy greens; the liver preferentially uses it to drive blood-clotting reactions. K2 (menaquinones, MK-4 through MK-13) is found in animal and fermented foods (and synthesized by gut bacteria), and it preferentially activates Gla proteins outside the liver — most importantly osteocalcin (bone) and matrix Gla protein (arteries). Conversion of K1 into K2 in humans is limited, so they are not freely interchangeable.
Should I take K2 with D3?
It's a biologically reasonable, low-risk pairing. D3 raises calcium absorption; K2 directs that calcium toward bone and away from arterial walls. Direct combination RCTs are limited, so the rationale is more mechanistic than outcome-proven. If your dietary K2 intake is already adequate (regular natto, hard cheeses, egg yolks), a separate K2 supplement is not strictly required.
MK-4 or MK-7 — which is better?
For everyday supplementation, MK-7 is the practical choice: half-life ~3 days, effective at 90–180 µg once daily. MK-4 has a half-life of only hours and requires roughly 45 mg/day in three divided doses (the Japanese osteoporosis prescription regimen) — vastly more material and expense. MK-4 is best understood as a pharmaceutical-megadose intervention for diagnosed osteoporosis under specialist care, not as a daily nutritional supplement.
Is vitamin K2 safe with warfarin?
Stable, consistent intake matters more than abstaining. Vitamin K antagonizes warfarin — that is how warfarin works — but a steady daily K2 intake simply lets the prescriber re-titrate the warfarin dose to the right INR. The dangerous move is starting, stopping, or sharply changing a K2 supplement without telling the clinician who manages your anticoagulation, so always loop them in and let them re-check the INR.
Related articles
Vitamin K1 vs K2
Two different vitamins with the same name — and why it matters for bone and arteries.
D3 and K2
The mechanistic case for the pairing, and where the evidence actually stops.
MK-4 vs MK-7
Half-life, dosing, cost, and what each form is actually used for.
K2 and Warfarin
Consistency, not abstinence — how to think about K2 on anticoagulants.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.